OM DENNE EPISODE
In Part 2 of this two-part “Engaging the Experts” interview, William Zellmer talks with Edward Li and James Stevenson regarding biosimilars, focusing on interchangeability and the integration of biosimilars into the medication-use system.
Faculty:
Edward C. Li, Pharm.D., M.P.H., BCOP, Activity Chair
Associate Professor
Department of Pharmacy Practice
University of New England College of Pharmacy
Portland, Maine
James G. Stevenson, Pharm.D., FASHP
Professor, Department of Clinical Pharmacy
University of Michigan College of Pharmacy
President, Hospital and Health System Services
Visante, Inc.
Ann Arbor, Michigan
C.E. Credits: This activity is not eligible for continuing education credits.
Engelsk
USA
UDSKRIFT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SØG BLANDT TIDLIGERE EPISODER
Søg efter gamle afsnit af ASHP Advantage's Engaging the Experts.
ANDRE EPISODE I DENNE PODCAST
Angela Cassano talks with Ryan Forrey about insourcing compounded sterile products and how he addressed the challenges faced at Emory University Hospital Midtown.
William Zellmer talks with John Petrich and Michael Storey about gene therapies and considerations for integrating them into pharmacy practice.
Part 1: Barriers to Optimizing the Use of Insulin in Managing Type 2 Diabetes
In Part 1 of this two-part “Engaging the Experts” interview, William Zellmer talks with Curtis L. Triplitt, Susan Cornell, and Joshua J. Neumiller regarding the barriers to optimizing the use of insulin in managing pati…
Part 2: Future Treatment Options and Roles for Pharmacists in Individualizing Insulin Therapy
In Part 2 of this two-part “Engaging the Experts” interview, William Zellmer talks with Curtis L. Triplitt, Susan Cornell, and Joshua J. Neumiller regarding future treatment options for type 2 diabete…
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra ASHP Advantage, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
REDIG
Tak fordi du hjælper med at holde podcast-databasen opdateret.
